Partial normalization of pubertal timing in female mice with DSS colitis treated with anti-TNF-α antibody.
BACKGROUND
Inflammatory bowel disease (IBD) and resultant colitis occurring prior to puberty are frequently associated with delayed puberty and losses of growth and bone mineralization. Some of this delay may be due to colonic inflammation and associated systemic inflammation. To date no treatments for IBD have been shown to normalize the timing of puberty. Our objective in this study was to determine whether there is a normalization of the timing of puberty during treatment of colitis using monoclonal antibodies (abs) to tumor necrosis factor (TNF)-α.


METHODS
We induced colitis in 23-day-old C57Bl6 female mice using 3% dextran sodium sulfate (DSS) for 7 days, followed by removal of DSS for an additional 3 days, resulting in 10 days of worsening colitis. DSS-treated mice received either TNF-α ab or Control ab on days 4 and 8 of colitis, while non-colitic Control mice received injections of TNF-α ab (Control + TNF-α ab). All groups were followed for the timing of vaginal opening until day of life 33, when they were euthanized for serum and colon collection.


RESULTS
The DSS + TNF-α ab group had lower levels of systemic interleukin (IL)-6 and a partial normalization of the timing of vaginal opening compared to the DSS + Control ab group. There were no differences in weight gain, growth, or colon histological inflammatory scores between the DSS + TNFα ab and DSS + Control ab groups over the course of the experiment.


CONCLUSIONS
We conclude that anti-TNF-α ab treatment causes a partial normalization of pubertal timing coincident with decreased systemic inflammation in DSS colitis. These data may have implications regarding growth and bone mineralization outcomes in pediatric IBD.
Division of Pediatric Endocrinology, University of Virginia, Charlottesville, VA 22908, USA. deboer@virginia.edu
Mark Daniel
MD
Deboer
Jeremy
J
Steinman
Yongli
Y
Li
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D003092:Colitis / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D016264:Dextran Sulfate; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004435:Eating / Q000187:drug effects; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005765:Gastrointestinal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006128:Growth / Q000187:drug effects; D000069285:Infliximab; D007986:Luteinizing Hormone / Q000097:blood; D051379:Mice; D008810:Mice, Inbred C57BL; D011628:Puberty, Delayed / Q000209:etiology / Q000517:prevention & control*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014621:Vagina / Q000187:drug effects / Q000254:growth & development; D015430:Weight Gain / Q000187:drug effects
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D016264:Dextran Sulfate; D000069285:Infliximab